Ed Kaye’s decades-long career has always centered around helping children with severe diseases, resulting in seven approved medicines that have helped change the lives of tens of thousands of people. Trained in pediatrics, pediatric neurology and biochemical genetics with a B.S. in biology from Loyola University and an M.D. from the Loyola University Stritch School of Medicine, he was on the research staff at Massachusetts General Hospital and Tufts University Medical Center and was the chief of biochemical genetics at the Children’s Hospital of Philadelphia. He was on the pediatric neurology staff at Boston Children’s Hospital until 2021.
In 2001, Dr. Kaye started the next phase of his career where he focused on translating promising science into new medicines for severe genetic diseases. He spent 10 years at Genzyme Corporation, most recently as group vice president of clinical development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. At Genzyme, Dr. Kaye also held various roles, including vice president of medical affairs for lysosomal storage diseases, vice president of clinical research and interim head of PGH global medical affairs. In 2011, he joined Sarepta Therapeutics as Chief Medical Officer leading the drive to develop Exondys 51 a pioneering drug for Duchenne muscular dystrophy. He went on to serve as CEO of Sarepta in 2015, where he led the successful push to win FDA approval of Exondys 51. He also served on Sarepta’s Board of Directors. From 2017 to 2025, Dr. Kaye served as Stoke Therapeutics’ CEO and Director. He currently serves as a member of the Boards of Directors at Stoke, Cytokinetics, Inc., Avidity Biosciences and the Massachusetts Biotechnology Council.
Dr. Kaye earned his B.S. in biology from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.
What is Edward M. Kaye's net worth?
The estimated net worth of Edward M. Kaye is at least $1.59 million as of December 3rd, 2025. Dr. Kaye owns 51,305 shares of Stoke Therapeutics stock worth more than $1,593,020 as of December 4th. This net worth estimate does not reflect any other investments that Dr. Kaye may own. Additionally, Dr. Kaye receives a salary of $948,900.00 as Director at Stoke Therapeutics. Learn More about Edward M. Kaye's net worth.
How old is Edward M. Kaye?
What is Edward M. Kaye's salary?
How do I contact Edward M. Kaye?
Has Edward M. Kaye been buying or selling shares of Stoke Therapeutics?
Over the course of the past ninety days, Edward M. Kaye has sold $1,879,887.47 of Stoke Therapeutics stock. Most recently, Edward M. Md Kaye sold 1,070 shares of the business's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $30.65, for a transaction totalling $32,795.50. Following the completion of the sale, the director now directly owns 51,305 shares of the company's stock, valued at $1,572,498.25. Learn More on Edward M. Kaye's trading history.
Who are Stoke Therapeutics' active insiders?
Are insiders buying or selling shares of Stoke Therapeutics?
In the last twelve months, insiders at the sold shares 31 times. They sold a total of 319,912 shares worth more than $6,612,569.40. The most recent insider tranaction occured on December, 3rd when insider Barry Ticho sold 2,014 shares worth more than $61,729.10. Insiders at Stoke Therapeutics own 9.5% of the company.
Learn More about insider trades at Stoke Therapeutics. Information on this page was last updated on 12/3/2025.
